5‐FU

:   5‐fluorouracil

CA

:   carbohydrate antigen

CDDP

:   cisplatin

CI

:   confidence interval

CR

:   complete response

EGFR

:   epidermal growth factor receptor

GC

:   gemcitabine and cisplatin

Gem‐FLP

:   5‐FU, leucovorin, gemcitabine and cisplatin

IFEP

:   ifosfamide, 5‐FU, etoposide, and cisplatin

IFL

:   irinotecan, 5‐FU, and leucovorin

IRIS

:   irinotecan and S‐1

ITP

:   ifosfamide, paclitaxel, and cisplatin

LN

:   lymph node

MVAC

:   methotrexate, vinblastine, adriamycin, and cisplatin

OS

:   overall survival

PD

:   progressive disease

PFS

:   progression‐free survival

PR

:   partial response

SD

:   stable disease

Keynote messageThe combination of CDDP + S‐1 is a potent first‐line chemotherapy regimen for patients with advanced or recurrent urachal cancer. We reviewed the cases of five patients who received CDDP + S‐1 chemotherapy. CDDP + S‐1 confers modest activity in these patients.

Introduction {#iju512066-sec-0005}
============

Urachal carcinoma is one of the rare malignancies because of its frequency of occurrence and poor results with clinical research. In locally advanced urachal carcinoma, curative surgical treatment is recommended. However, in the recurrent or metastatic disease, any standard chemotherapy regimens have not been established yet.

The 5‐year survival rate of patients with urachal carcinoma is \<50%, which is poorer than the average cancer survival rate;[1](#iju512066-bib-0001){ref-type="ref"}, [2](#iju512066-bib-0002){ref-type="ref"} this is because no standard chemotherapy regimen is available for the patients thus far. Some groups have used CDDP‐based chemotherapy regimens for bladder carcinoma, but both MVAC and GC regimens have been insufficient to control the malignancy,[1](#iju512066-bib-0001){ref-type="ref"}, [3](#iju512066-bib-0003){ref-type="ref"} while ITP regimen for urothelial tracts showed that one of six patients with urachal carcinoma achieved CR.[4](#iju512066-bib-0004){ref-type="ref"} Meanwhile, the immunohistochemical profile of urachal adenocarcinoma is similar to that of colorectal adenocarcinoma; CK20 and CDX2 are usually positive in both types, while CK7 positivity is variable.[5](#iju512066-bib-0005){ref-type="ref"} Moreover, similar to colorectal adenocarcinoma, urachal adenocarcinoma could also have microsatellite instability and KRAS mutations.[6](#iju512066-bib-0006){ref-type="ref"} Currently, many clinical groups use the chemotherapy regimens for colon carcinomas in treating urachal carcinoma patients: IFL, modified FOLFOX6, and IRIS.[7](#iju512066-bib-0007){ref-type="ref"}, [8](#iju512066-bib-0008){ref-type="ref"}, [9](#iju512066-bib-0009){ref-type="ref"}

Siefker‐Radtke *et al*. have reported effective outcomes with several chemotherapy regimens including both 5‐FU and CDDP.[1](#iju512066-bib-0001){ref-type="ref"} At the MD Anderson Cancer Center, investigators implemented a phase II trial of Gem‐FLP originally for adenocarcinomas of the urothelial tract and urachal remnant.[10](#iju512066-bib-0010){ref-type="ref"}, [11](#iju512066-bib-0011){ref-type="ref"} The IFEP regimen, originally for advanced bladder cancer, was also applied to patients with urachal carcinoma.[12](#iju512066-bib-0012){ref-type="ref"} It is essential that the S‐1 plus CDDP combination chemotherapy is the standard first‐line treatment for patients with advanced gastric cancer.[13](#iju512066-bib-0013){ref-type="ref"} Also, CDDP + S‐1 chemotherapy regimen has been reported to have some presumptive advantage in patients with urachal adenocarcinoma.[12](#iju512066-bib-0012){ref-type="ref"}, [14](#iju512066-bib-0014){ref-type="ref"} In the present study, we retrospectively analyzed the clinical outcomes of patients with urachal adenocarcinoma treated with CDDP + S‐1 chemotherapy in our institution.

Case presentation {#iju512066-sec-0006}
=================

This study was approved by the Institutional Review Board of the National Cancer Center of Japan. Patients were eligible if they had confirmed adenocarcinoma of urachal origin, as determined histologically and by imaging. We retrospectively reviewed five patients who had been treated with CDDP + S‐1 first‐line chemotherapy regimen in our institution from June 2011 to March 2014.

The dosage and administration schedule of S‐1 + CDDP were according to that in a previous report.[13](#iju512066-bib-0013){ref-type="ref"} S‐1, an oral 5‐FU derivative consisting of tegafur, gimeracil, and oteracil potassium, was administered orally at a dose of 80 mg/m^2^ per day for 21 consecutive days, followed by 14‐day rest. CDDP was administered intravenously for over 2 h at a dose of 60 mg/m^2^ per day on Day 8 of each cycle. Treatment was repeated every 35 days up to a maximum of six cycles or unless disease progression was observed.

The diagnosis of urachal carcinoma was based on the MD Anderson Cancer Center criteria.[15](#iju512066-bib-0015){ref-type="ref"} Clinical, laboratory, radiographic, therapeutic, and pathologic data for each individual were retrieved from medical records. Tumors were staged by both the Sheldon and Mayo staging systems.[2](#iju512066-bib-0002){ref-type="ref"}, [16](#iju512066-bib-0016){ref-type="ref"} Imaging data were reviewed according to the Response Evaluation Criteria in Solid Tumors version 1.1 criteria,[17](#iju512066-bib-0017){ref-type="ref"} and classified as CR, PR, SD, or PD.

Toxicity was graded according to the Common Terminology Criteria for Adverse Events v4.0. All statistical assessments were performed using the statistical package IBM SPSS version 23.0 (SPSS Inc., Chicago, IL, USA).

Cohort characteristics {#iju512066-sec-0008}
======================

Five patients with urachal adenocarcinoma received treatment with CDDP + S‐1. Clinical characteristics of the patients are shown in Table [1](#iju512066-tbl-0001){ref-type="table"}.

###### 

Characteristics of five patients with urachal carcinoma treated with CDDP + S‐1 chemotherapy

  Characteristics                                        No. of patients                                                           
  ------------------------------------------------------ ------------------------------------------------------------------------- -----------
  Sex                                                    Male/female                                                               3/2
  Age at diagnosis                                       \<55 years/55 years or more                                               2/3
  Symptoms and signs                                     Macroscopic hematuria/micturition pain/upper abdominal pain               3/1/1
  Sheldon tumor stage                                    IIIA/IVA/IVB                                                              3/1/1
  Mayo tumor stage                                       II/III/IV                                                                 3/1/1
  Histology                                              Adenocarcinoma: mucinous type/mixed type/not otherwise specified          5: 3/1/1
  Cystectomy                                             Partial/radical/no                                                        4/0/1
  LN dissection                                          Yes/no                                                                    3/2
  Chemotherapy                                           For metastatic disease/salvage (for recurrence)                           1/4
  Tumor marker[†](#iju512066-note-0001){ref-type="fn"}   Carcinoembryonic antigen/CA19‐9/CA125/none                                4/1/1/1
  Family history of cancer                               Colon cancer/other cancers/none                                           2/3/0
  Metastatic/recurrent site                              LN/lung/peritoneum/liver/bone                                             3/2/1/1/1
  Smoking                                                Heavy smoker (\>30 pack‐years)/light smoker (≤30 pack‐years)/non‐smoker   2/1/2
  Drinking                                               Regular drinker/occasional drinker/non‐drinker                            3/1/1

†One patient showed elevated serum level of all three markers.
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Response and patient outcomes {#iju512066-sec-0009}
=============================

Case summaries of all five patients with urachal adenocarcinoma, treated with CDDP + S‐1 chemotherapy, are shown in Table [2](#iju512066-tbl-0002){ref-type="table"}. Four patients achieved SD and the other had PD, while no patients achieved either CR or PR. Only one patient completed six cycles of CDDP + S‐1 chemotherapy. The disease control rate (proportion of patients with best response of CR or PR or SD) was 80%. For PFS and OS, the survival curves were estimated using the Kaplan--Meier method. Our case series demonstrates a median PFS and OS were 7.0 months (95% CI 2.5, 11.5) and 22.4 months (95% CI 0.0, 45.6), respectively (Fig. [1](#iju512066-fig-0001){ref-type="fig"}).

###### 

Case summaries of five patients with urachal carcinoma treated by CDDP + S‐1 chemotherapy

  No.   Age/sex     Chief complaint         Histology (adenocarcinoma)                                    Stage                   Status                               Surgery     Eastern Cooperative Oncology Group performance status                                                                                                                    S‐1/CDDP (cycles)   Best overall response   
  ----- ----------- ----------------------- ------------------------------------------------------------- ----------------------- ------------------------------------ ----------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ------------------- ----------------------- ----
  1     67/male     Macroscopic hematuria   With signet‐ring cell carcinoma (mucin‐producing)             IIIA → IVB (LN, bone)   II → IV                              Recurrent   *En bloc* segmental resection                                                                                                                                            1                   2                       SD
  2     63/male     Macroscopic hematuria   Poorly differentiated                                         IVA (LN)                III                                  Recurrent   *En bloc* segmental resection with pelvic lymph node dissection                                                                                                          0                   4                       SD
  3     53/male     Upper abdominal pain    Well differentiated (mucin‐producing)                         IVB (LN, lung, liver)   IV                                   Advanced    Not performed (inoperable)                                                                                                                                               0                   1                       PD
  4     47/female   Micturition pain        Well to moderately differentiated tubular (mucin‐producing)   IIIA → IIIC             II → IV (peritoneal dissemination)   Recurrent   *En bloc* segmental resection with bilateral lymphadenectomy Excision of the recurrent tumors and abdominal wall reconstruction using a right anterolateral thigh flap   0                   2                       SD
  5     61/female   Macroscopic hematuria   Well to moderately differentiated                             IIIA → IVB              II → IV (lung)                       Recurrent   Laparoscopic *en bloc* partial cystectomy with bilateral lymphadenectomy                                                                                                 0                   6                       SD
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![Kaplan--Meier curves of (a) PFS and (b) OS.](IJU5-2-150-g001){#iju512066-fig-0001}

Toxicity {#iju512066-sec-0010}
========

The adverse events are shown in Table [3](#iju512066-tbl-0003){ref-type="table"}. Of the five patients, three experienced one episode of grade 3 toxicity. There were no therapy‐related deaths.

###### 

Major adverse events that occurred in five patients with urachal carcinoma treated with CDDP + S‐1 chemotherapy

  Adverse event                          No. of patients                              
  -------------------------------------- -------------------------------------------- ---
  Hematological                                                                       
  Thrombocytopenia                       3                                            0
  Leukocytopenia                         3                                            0
  Anemia                                 2                                            1
  Neutropenia                            1                                            0
  Non‐hematological                                                                   
  Constipation                           3                                            0
  Increased alkaline phosphatase level   3                                            0
  Hyperglycemia                          3                                            0
  Hypoalbuminemia                        3                                            0
  Hypertension                           1                                            1
  Thromboembolic event                   1                                            1
  Total                                  58[†](#iju512066-note-0002){ref-type="fn"}   3

†The number includes the cases omitted from this table.
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Discussion {#iju512066-sec-0011}
==========

This study is a single‐institution case series of patients with urachal adenocarcinoma treated with CDDP + S‐1 chemotherapy.

The efficacy of CDDP + S‐1 chemotherapy has been previously reported in a patient with recurrent urachal carcinoma.[14](#iju512066-bib-0014){ref-type="ref"} The combination of S‐1 + CDDP has been considered one of the most promising chemotherapy regimens against urachal adenocarcinoma. In a recent study, CDDP + S‐1 regimen showed that two of six patients with urachal carcinoma achieved PR.[12](#iju512066-bib-0012){ref-type="ref"} To date, CDDP + S‐1 did not show any obvious safety problems in patients with urachal carcinoma.[12](#iju512066-bib-0012){ref-type="ref"}, [14](#iju512066-bib-0014){ref-type="ref"} The combination chemotherapy was also well tolerated in our study. Meanwhile, our study showed modest outcome in urachal carcinoma patients treated with CDDP + S‐1 chemotherapy. The low response rate of our study suggests the necessity of more active treatment for urachal carcinoma. Currently, the molecular‐targeted therapy has been employed widely across the tumor type. Such approach should be integrated into the treatment of urachal carcinoma. A recent report showed that a patient with metastatic wild‐type KRAS urachal cancer responded well to cetuximab, a chimeric mouse‐human monoclonal antibody targeting the human EGFR.[18](#iju512066-bib-0018){ref-type="ref"} In considering anti‐EGFR antibody therapy, patients with urachal adenocarcinoma should be tested for the presence of KRAS and BRAF mutations prior to therapy.[19](#iju512066-bib-0019){ref-type="ref"}

The major limitations of our study include the retrospective design, the small study cohort derived from a single institution, and rarity of the disease. Larger sample sizes could help determine the feasibility of the chemotherapy regimen, but patients with rare tumors may show similar treatment responses.

In conclusion, we reviewed the cases of five patients with urachal adenocarcinoma who received CDDP + S‐1 chemotherapy. CDDP + S‐1 confers modest activity for patients with advanced or recurrent urachal carcinoma, as indicated from the findings of previous reports and our study. To improve outcomes for urachal carcinoma patients, more efficacious treatment will be needed in the future.
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